Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Merck & Co., Inc. (MRK) vs Invesco Preferred ETF (PGX) Price & Performance

Merck & Co., Inc.Trade
Invesco Preferred ETFTrade

Price performance (Past 24H)

Key statistics

Merck & Co., Inc. vs Invesco Preferred ETF — how do they compare? Merck & Co., Inc. trades at $130.11 (market cap $323.00B), while Invesco Preferred ETF trades at $10.64. The key difference: Merck & Co., Inc. pays a 2.6% dividend while Invesco Preferred ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Invesco Preferred ETF nearer its low. Which is the better fit depends on your goals.

MRKPGX
Market Cap
$323.00B
Sector
Health
52-Week High
$131.84$11.87
52-Week Low
$77.60$10.65
Enterprise Value
$369.77B
Dividend Yield
2.6%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Merck & Co., Inc.

Merck (MRK) trades at $130.90, up 1.81% on the day, with a bullish technical outlook and strong institutional support. Recent earnings beats in Q4 2025 and Q1-Q2 2026, alongside a 28.07% net income margin in 2025, highlight operational strength. The acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, though a high P/E of 104.74 signals premium valuation. Cash flow remains positive at $1.37B in 2025, but investing outflows have increased.

The stock offers growth potential from pipeline expansion and analyst consensus targeting $140.36, but risks include elevated debt-to-asset ratios (36.06% in 2025) and competitive pressures. Investors should weigh robust profitability against valuation concerns and macroeconomic headwinds affecting the pharma sector.

Invesco Preferred ETF

PGX trades at $10.72 with a slight 0.28% daily gain. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. The stock faces resistance at $11 across multiple levels. Recent corporate actions include scheduled dividends for mid-2026, but current financial ratios and income statements lack available data for fundamental assessment.

The outlook remains cautious due to bearish technical signals and limited fundamental visibility. Investment opportunities hinge on future financial disclosures and business developments, while risks include technical downtrend continuation and potential volatility from unresolved financial metrics.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK

About Invesco Preferred ETF

The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.

Read more on PGX